Hansa Biopharma is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead projet imlifidase (IdeS) is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients with significant potential for further development in other solid organ transplants and a wide range of acute autoimmune indications.
The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Biopharma technology into relapsing autoimmune diseases and potentially oncology.
Workplace & Culture
We are based in Lund, Sweden, and we pride ourselves on providing a supportive team structure and offering numerous opportunities for staff from different departments to work together, sharing knowledge and learning from each other.
Our future as a dynamic organisation is largely dependent on the knowledge, creativity and skills of our employees. We have an informal and flexible work environment, providing numerous opportunities for professional and personal development.
